Diaceutics (LON:DXRX) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Diaceutics (LON:DXRX) in a research note released on Tuesday morning,Digital Look reports. They currently have a GBX 160 ($2.03) target price on the stock.

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($2.03) price target on shares of Diaceutics in a research report on Tuesday.

Diaceutics Stock Performance

DXRX stock traded down GBX 3.50 ($0.04) on Tuesday, hitting GBX 120.50 ($1.53). The company had a trading volume of 35,123 shares, compared to its average volume of 108,035. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 2.93. Diaceutics has a 12-month low of GBX 84.50 ($1.07) and a 12-month high of GBX 136 ($1.73). The stock has a market cap of £101.79 million, a price-to-earnings ratio of -4,016.67 and a beta of 0.58. The stock’s 50-day simple moving average is GBX 122.28 and its 200 day simple moving average is GBX 126.30.

Diaceutics Company Profile

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.